NCT05321875View on ClinicalTrials.gov

Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)

PHASE3RecruitingINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

June 2, 2022

Primary Completion Date

June 2, 2026

Study Completion Date

June 2, 2026

Conditions
Cardiomyopathy, Dilated
Interventions
DRUG

Candesartan

3 years treatment with candesartan target dose: 32 mg or maximum tolerated dose after dose escalation from 16 mg

Trial Locations (1)

28222

RECRUITING

Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda

All Listed Sponsors
lead

Cristina Avendaño Solá

OTHER